EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial

Patrick Lewicki iD, Arnav Srivastava, Ralph Jiang, Anna Johnson, Khurshid Ghani, Kevin Ginsburg, Tudor Borza, Kristian Stensland, Simpa S Salami, Elai Davicioni, Rodney L Dunn, Stephanie Daignault-Newton und 7 weitere

JNCI Cancer Spectrum · 09.05.2026 · 10 (3)

DOI: 10.1093/jncics/pkag040 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 24.04.2026. Verfasst von Patrick Lewicki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Michigan, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Salvage Therapy. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Issues with randomized controlled trial generalizability are well described, but whether these issues result from differences in patient treatment across contexts remains unknown. We studied treatment of patients with high-risk prostate cancer after radical prostatectomy inside and outside a randomized controlled trial evaluating the impact of a genomic classifier on post–radical prostatectomy treatment decision making (Genomics in Michigan Impacting Observation of Radiation [G-MINOR]; ClinicalTrials.gov identifier NCT02783950).

Methods

G-MINOR enrolled 338 patients; propensity score–matched eligible but unenrolled patient cohorts (pretrial and trial contemporary) from the Michigan Urological Surgery Improvement Collaborative (MUSIC), in which the trial was embedded, were compared for rates and time to secondary treatment (adjuvant or salvage therapy) after prostatectomy.

Results

Among 338 patients in the G-MINOR cohort, 69 (31 adjuvant, 38 salvage) received secondary treatment compared with 266 (183 adjuvant, 83 salvage) and 104 (60 adjuvant, 44 salvage) in the 1014 contemporary and 338 pretrial–matched MUSIC cohorts. Time to secondary treatment was much shorter in the MUSIC cohort across all comparisons. For example, matching G-MINOR to synchronous MUSIC patients demonstrated 84% vs 74% estimated 2-year treatment-free survival for trial and real-world patients, respectively (P < .001).

Conclusions

Controlling for key clinicopathologic factors, patients in the G-MINOR randomized controlled trial and MUSIC cohorts were treated differently, even after stratifying by genomic risk. These findings suggest that challenges in randomized controlled trial generalizability extend beyond the representativeness of trial participants. Differences in management may also explain why divergent patient outcomes are observed in randomized controlled trials vs real-world settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatectomyProstatic NeoplasmsRandomized Controlled Trials as TopicSalvage TherapyAgedHumansMaleMiddle AgedPropensity ScoreRadiotherapy, AdjuvantTime Factors

Autor:innen und Institutionen

  • Department of Urology, University of Michigan, Ann Arbor, MI, United States.
  • Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States.
  • Department of Urology, Wayne State University, Detroit, MI, United States.
  • Veracyte, Inc, South San Francisco, CA, United States.
  • Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, United States.
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States.

ORCID-Profile: Patrick Lewicki, Robert T Dess, Todd M Morgan

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Lewicki, P., Srivastava, A., Jiang, R., Johnson, A., Ghani, K., Ginsburg, K., Borza, T., Stensland, K., Salami, S. S., Davicioni, E., Dunn, R. L., Daignault-Newton, S., Palapattu, G. S., Spratt, D. E., Cher, M., Schipper, M., Dess, R. T., Morgan, T. M., & Singhal, U. (2026). Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial. JNCI Cancer Spectrum, 10(3). https://doi.org/10.1093/jncics/pkag040

Vancouver

Lewicki P, Srivastava A, Jiang R, Johnson A, Ghani K, Ginsburg K, et al. Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial. JNCI Cancer Spectrum. 2026;10(3). doi:10.1093/jncics/pkag040

BibTeX
@article{Lewicki2026,
  author = {Lewicki, Patrick and Srivastava, Arnav and Jiang, Ralph and Johnson, Anna and Ghani, Khurshid and Ginsburg, Kevin and Borza, Tudor and Stensland, Kristian and Salami, Simpa S and Davicioni, Elai and Dunn, Rodney L and Daignault-Newton, Stephanie and Palapattu, Ganesh S and Spratt, Daniel E and Cher, Michael and Schipper, Matthew and Dess, Robert T and Morgan, Todd M and Singhal, Udit},
  title = {Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1093/jncics/pkag040}
}
Kostenlos starten →